(Q42947269)

English

Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B.

scientific article published on September 2010

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

0 references

liver cirrhosis

0 references

1 reference

based on heuristic

inferred from title

chronic hepatitis

1 reference

based on heuristic

inferred from title

2

0 references

object named as

Ching-Lung Lai

6

0 references

Waldemar Halota

9

object named as

Waldemar Halota

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Uchenna H. Iloeje

14

object named as

Uchenna Iloeje

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

author name string

Ting-Tsung Chang

1

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Shun-Sheng Wu

3

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Eugene Schiff

4

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Kwang-Hyub Han

5

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Rifaat Safadi

7

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Samuel S Lee

8

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Zachary Goodman

10

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Yun-Chan Chi

11

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Hui Zhang

12

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Robert Hindes

13

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Suzanne Beebe

15

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Bruce Kreter

16

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

language of work or name

0 references

publication date

1 September 2010

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

number of pages

8

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

52

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

886-893

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23785

21 January 2018

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23785

21 January 2018

Predicting cirrhosis risk based on the level of circulating hepatitis B viral load

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23785

21 January 2018

Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23785

21 January 2018

Role of hepatitis B viral load and basal core promoter mutation in hepatocellular carcinoma in hepatitis B carriers

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23785

21 January 2018

High viral load is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23785

21 January 2018

Is liver fibrosis reversible?

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23785

21 January 2018

Mechanisms of hepatic fibrogenesis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23785

21 January 2018

The role and regulation of hepatic stellate cell apoptosis in reversal of liver fibrosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23785

21 January 2018

Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23785

21 January 2018

Apoptosis of hepatic stellate cells: involvement in resolution of biliary fibrosis and regulation by soluble growth factors

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23785

21 January 2018

Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23785

21 January 2018

Regression of hepatic fibrosis in hepatitis C with long-term interferon treatment

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23785

21 January 2018

Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23785

21 January 2018

Reversibility of cirrhosis in patients cured of thalassemia by bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23785

21 January 2018

Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23785

21 January 2018

Alpha-interferon improves liver fibrosis in chronic hepatitis C: clinical significance of the serum N-terminal propeptide of procollagen type III.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23785

21 January 2018

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23785

21 January 2018

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23785

21 January 2018

Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23785

21 January 2018

Lamivudine for patients with chronic hepatitis B and advanced liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23785

21 January 2018

Histological outcome during long-term lamivudine therapy.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23785

21 January 2018

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23785

21 January 2018

Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23785

21 January 2018

EASL Clinical Practice Guidelines: management of chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23785

21 January 2018

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23785

21 January 2018

Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23785

21 January 2018

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23785

21 January 2018

Histological grading and staging of chronic hepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23785

21 January 2018

Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23785

21 January 2018

Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23785

21 January 2018

Antiviral therapy reduces portal pressure in patients with cirrhosis due to HBeAg-negative chronic hepatitis B and significant portal hypertension.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23785

21 January 2018

Reversibility of cirrhosis in chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23785

21 January 2018

Risk and predictors of mortality associated with chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23785

7 January 2021

based on heuristic

inferred from DOI database lookup

Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23785

7 January 2021

based on heuristic

inferred from DOI database lookup

Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23785

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/HEP.23785

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42947269&oldid=1765800376"